摘要
目的探讨齐拉西酮与奥氮平对首发女性精神分裂症患者的疗效、体重、血糖、血脂的影响。方法将60例首发女性精神分裂症患者随机分为齐拉西酮组与奥氮平组,每组30例,随访8周。于治疗前、治疗第4、8周末分别测定阳性与阴线症状量表(PANSS)、体重、血糖、血脂。结果 2组治疗前后PANSS评分差异均有统计学意义(P<0.05),4周末齐拉西酮组阳性症状分及总分显著高于奥氮平组(P<0.05),但8周末2组间疗效的差异无统计学意义(P>0.05);齐拉西酮对体重、血糖、血脂影响显著小于奥氮平,差异均有统计学意义(P<0.05)。结论 2组的总体疗效相当;齐拉西酮组与对女性首发精神分裂症患者的体重、血糖、血脂无明显影响,而奥氮平对体重、血糖、血脂有明显影响。
Objective To study the influence of ziprasidone and olanzapine on the efficacy, weight, blood sugar and blood lipid in the treatment of first-episode female patients with schizophrenia. Methods A total of 60 female patients with first-episode schizophrenia were randomly divided into 2 groups receiving ziprasidone and olanzapine for 8 w, respectively. Positive and negative symptom scale （PANSS） was used to evaluate the treatment effect and the side effects, They were determined respectively for the efficacy, weight, blood sugar and blood lipid in and blood lipid in the 4th weekend and 8th weekend. Results After treatment, the scores of PANSS of 2 groups were both significantly decreased （P 〈 0.01 ）, the ziprasidone＇ s positive symptoms and total score were significantly higher than olanzapine in the 4th weekend （P 〈 0.05 ）, but the efficacy between the 2 groups was no significant difference in the 8th weekend （P 〉 0.05 ） ; Effects on weight, blood glucose, and blood lipid of ziprasidone were significantly less than those of olanzapine, they were significantly different between 2 groups （ P 〈 0.05 ）. Conclusion Ziprasidone and olanzapine has similar efficacy ; Ziprasidone has no effects on weight, blood sugar and blood lipid of first-episode female patients with schizophrenia, but olanzapine has significant effects on weight, blood sugar and blood lipid.
出处
《今日药学》
CAS
2012年第7期410-412,共3页
Pharmacy Today
关键词
齐拉西酮
奥氮平
精神分裂症
体重
血糖
血脂
ziprasidone
olanzapine
schizophrenia
weight
blood sugar
blood lipid
